The melanoma-associated antigen-A3, -A4 genes: Relation to the risk and clinicopathological parameters in breast cancer patients

Molecular and Cellular Biochemistry

Volumn 351, Issue 1-2, 2011, Pages 261-268

  Hussein, Yousri M ^a   Gharib, Amal F ^a   Etewa, Rasha L ^a   El Shal, Amal S ^a   Abdel Ghany, Mohamed Esmat ^b   Elsawy, Wael H ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Breast cancer; MAGE A3 and MAGE A4; Neoplasm metastasis

Indexed keywords

BETA ACTIN; ESTROGEN RECEPTOR; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MESSENGER RNA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CANCER RISK; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTIGENS, NEOPLASM; BASE SEQUENCE; BREAST NEOPLASMS; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79953721153     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0734-4     Document Type: Article

References (44)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds) (2002) SEER Cancer Statistics Review, 1973-1999, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1973-1999/
2. Ballestrero A, Garuti A, Bertolotto M, Rocco I, Boy D, Nencioni A, Ottonello L, Patron F (2005) Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer 92:1948-1952 (Pubitemid 40826146)
3. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365:1687-1717
4. Sabbatini R, Federico M, Morselli M, Depenni R, Cagossi K, Luppi M, Torelli G, Silingardi V (2000) Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy. J Clin Oncol 18:1914-1920 (Pubitemid 30261929)
5. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kap TC, Ponniah S, Peoples GE, Moroni M (2007) HYOU1/Orp150 expression in breast cancer. Med Sci Monit 13:BR231-BR239
6. Gonzalez-Mancha R, Galan JJ, Crespo C, Iglesias PL, Gonzalez-Perez A, Moron FJ, Moreno Nogueira JA, Real LM, Pascual MH, Ruiz A, Royo JL (2008) Analysis of the ERalpha germline PvuII marker in breast cancer risk. Med Sci Monit 14:CR136-CR143
7. Krismann M, Todt B, Schroder J, Gareis D, Muller KM, Seeber S, Schutte J (1995) Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 13:2769-2775
8. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS (1998) Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632-2640 (Pubitemid 28363026)
9. Bae JW, Choi KH, Kim HG, Park SH (2000) The detection of circulating breast cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. J Korean Med Sci 15:194-198
10. Silva AL, Diamond J, Silva MR, Passos-Coelho JL (2001) Cytokeratin 20 is not a reliable molecular marker for occult breast cancer cell detection in hematological tissues. Breast Cancer Res Treat 66:59-66 (Pubitemid 32397943)
11. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, Arrigoni G, Bregni M, Pileri A, Gianni AM (2001) Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol 12:1693-1698 (Pubitemid 34105658)
12. Fabisiewicz A, Kulik J, Kober P, Brewczynska E, Pienkowski T, Sieldlecki JA (2004) Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta Biochim Pol 51:747-755 (Pubitemid 39296928)
13. Potemski P, Kusinska R, Pasz-Walczak G, Piekarski JH, Watala C, Pluciennik E, Bednarek AK, Kordek R (2009) Prognostic relevance of cyclin E expression in operable breast cancer. Med Sci Monit 15:MT34-MT40
14. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens; gametogenesis and cancer. Nat Rev Cancer 5:615-625
15. Zendman AJ, Ruiter DJ, Van Muijen GN (2003) Cancer/testis-associated genes. Identification, expression profile, and putative function. J Cell Physiol 194:272-288 (Pubitemid 36176890)
16. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1-15
17. Hofmann M, Ruschenburg I (2002) mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Cancer 96:187-193
18. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA (2002) Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 62:3971-3979 (Pubitemid 34791062)
19. Marinez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J, Amancio-Chassin O, Ordonez RM, Montesinos JJ, Mayani H, McCurdy DK, Ostrosky-Weqman P, Garrido-Guerrero E, Miranda E (2007) mRNA expression of MAGE-A3 gene in leukemia cells. Leukemia Res 31:33-37 (Pubitemid 44709750)
20. Ferris RL (2004) Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorhinolaryng Relat Spec 66:332-340
21. Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL (2004) Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 27:329-338 (Pubitemid 39121921)
22. Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T (2004) Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90:838-843 (Pubitemid 38406595)
23. Tian XX, Rai D, Li J, Zou C, Bai Y, Wazer D, Band V, Gao Q (2005) BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res 65:4747-4753
24. Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C (2004) Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 12:145-151
25. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. PNAS (USA) 93:7149-7153 (Pubitemid 26243517)
26. De Smet C, Loriot A, Boon T (2004) Promoter dependent mechanism leading to selective hypomethylation within the 5-region of gene MAGE-A1 in tumor cells. Mol Cell Biol 24:4781-4790 (Pubitemid 38668044)
27. Loriot A, De Plaen E, Boon T, De Smet C (2006) Transient down-regulation of DNMT1 methyl transferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem 281:10118-10126 (Pubitemid 43864547)
28. John T, Caballero OL, Svobodova SJ, Kong A, Chua R, Browning J, Fortunato S, Deb S, Hsu M, Gedye CA, Davis D, Altorki N, Simpson AJ, Chen YT, Monk M, Cebon JS (2008) ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clin Cancer Res 14:3291-3298
29. Chen CH, Huang GT, Lee HS, Yang PM, Yan MD, Chen DS, Sheu JC (1999) High genes frequency in human of expression of MAGE hepatocellular carcinoma. Liver 19:110-114
30. Bloom HJG, Richardson WW (1957) Histopathological grading and prognosis in breast cancer. Br J Cancer 11:359-377
31. Breast. AJCC cancer staging manual (2002) In: American joint committee on cancer, 6th edn. Springer, New York, pp 171-180
32. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225-249
33. Lugo TG, Braun S, Cote RJ, Pantel K, Rusch V (2003) Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21:2609-2615 (Pubitemid 46606345)
34. Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339-351
35. Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano EA, Hoon DSB (2001) Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay correlation with clinical stage of disease. Cancer Res 62:8845-8850 (Pubitemid 34013899)
36. Wascher RA, Bostick PJ, Huynh KT, Turner R, Qi K, Giuliano AE, Hoon DSB (2001) Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. Br J Cancer 85:1340-1346 (Pubitemid 33081930)
37. Fujie T, Mori M, Ueo H, Sugimachi K, Akiyoshi T (1997) Expression of MAGE and BAGE genes in Japanese breast cancers. Ann Oncol 8:369-372 (Pubitemid 27230978)
38. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F, Pantel K (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61:6682-6687 (Pubitemid 32896486)
39. Bandić D, Juretić A,Šarčević B,Šeparović V, Tiljak MK, Hudolin T, Spagnoli GC, Čović D, Šamija M (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal beast cancer: retrospective immunohistochemical study. Croat Med J 47:32-41
40. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Kido T, Mayer RJ, Arii S, Fujita J (2000) Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 6:96-99 (Pubitemid 30048534)
41. Higashitsuji H, Liu Y, Mayer RJ, Fujita J (2005) The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. Cell Cycle 4:1335-1337 (Pubitemid 41437115)
42. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ (2006) Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol 16:229-233 (Pubitemid 43728872)
43. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, Itoh K, Fujita J (2003) MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278:10668-10674 (Pubitemid 36800336)
44. Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113-1124 (Pubitemid 29330549)